

This patient group direction (PGD) must only be used by registered health professionals who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version of the PGD should be used.

Patient Group Direction (PGD)

For the supply of

Hydrocortisone 0.5% or 1% Cream

By registered health care professionals for

Management of Mild Inflammatory Skin Disorders

Throughout the Manx Care and those contracted by the Manx Care where appropriate within practice

PGD NUMBER 93

1. Change history

Version number	Change details	Date
1	Original PGD ratified	June 2021
2	Minor word changes to ensure clarity to the PGD	September 2023

Reference number: 93 Valid from: 03/2023 Review date: 09/2025 Version: 2

2. Medicines practice guideline 2: Patient group directions

Refer to the relevant sections of NICE medicines practice guideline 2: *Patient group directions* as stated in the blank template notes. For further information about PGD signatories, see the NHS and Manx Care <u>PGD website FAQs</u>

3. PGD development

Refer to the <u>NICE PGD competency framework for people developing PGDs</u>

Job Title & organisation	Name	Signature	Date
Author of the PGD			
Member of the PGD working group			

4. PGD authorisation

Refer to the <u>NICE PGD competency framework for people authorising PGDs</u>

Job Title	Name	Signature	Date
Medical Director			
Deputy to			
Chief Pharmacist/			
Pharmaceutical Adviser			
Senior Paramedic			
Director of Nursing			
GP Adviser			
Senior Microbiologist (if PGD contains antimicrobials)	N/A	N/A	N/A

Reference number: 93 Valid from: 03/2023 Review date: 09/2025

Version: 2 Page 2 of 5

5. Training and competency of registered healthcare professionals, employed or contracted by the Manx Care, GP practice or Hospice

Refer to the NICE PGD competency framework for health professionals using PGDs

	Requirements of registered Healthcare professionals working under the PGD
Qualifications and professional registration	 Registered healthcare professionals, working within or contracted by the Manx Care, GP practice or Hospice who are permitted staff groups outlined within the current PGD policy Pharmacists must be practising in Manx Care authorised premises i.e. contracted pharmacy premises
Initial training	 Knowledge of current guidelines and the administration of the drug specified in this PGD/BNF and of the inclusion and exclusion criteria Training which enables the practitioner to make a clinical assessment to establish the need for the medication covered by this PGD Local training in the use of PGDs
Competency	Staff will be assessed on their knowledge of drugs and clinical
assessment	assessment as part the competency framework for registered health professionals using PGDs
Ongoing training and	The registered health care professionals should make sure they are
competency	aware of any changes to the recommendations for this medication;
	it is the responsibility of the registered health care professionals to
	keep up to date with continuing professional development. PGD
	updates will be held every two years

6. Clinical Conditions

Clinical condition or situation to which this PGD applies	Management of mild inflammatory skin disorders
Inclusion criteria	Adults and children 2 years and over presenting with:
	Insect bite reactions
	Allergic contact dermatitis
	Mild to moderate eczema
Exclusion criteria	Children under the age of 2 years
	Known hypersensitivity to the preparation
	Application to eyes, anogenital region, and broken or infected
	skin
	Application to face (1% cream only)
	• Skin lesions caused by infection ie, cold sores, chicken pox, acne,
	athlete's foot, ringworm or impetigo

Reference number: 93 Valid from: 03/2023 Review date: 09/2025

Version: 2

Cautions (including any relevant action to be	 Pregnancy – inadequate evidence of safety Prolonged use on the face is not recommended 	
taken)	Froionged use on the face is not recommended	
	A detailed list of cautions is available in the SPC, which is available	
	from the electronic Medicines Compendium website:	
	www.medicines.org.uk and BNF https://bnf.nice.org.uk	
Arrangements for referral	Patient should be referred to a more experienced clinical	
for medical advice	practitioner for further assessment	
Action to be taken if	Patient should be referred to a more experienced clinical	
patient excluded	practitioner for further assessment	
Action to be taken if	A verbal explanation should be given to the patient on: the need	
patient declines	for the medication and any possible effects or potential risks	
treatment	which may occur as a result of refusing treatment	
	This information must be documented in the patients' health	
	records	
	Any patient who declines care must have demonstrated capacity	
	to do so	
	Where appropriate care should be escalated	

7. Details of the medicine

Name, form and strength	Hydrocortisone 0.5% or 1% cream
of medicine	
Legal category	Prescription Only Medicine (POM) or Pharmacy (P)
Indicate any off-label use	None
(if relevant)	
Route/method of	Topical – for external use only
administration	
Dose and frequency	Apply thinly to affected area(s) 1-2 times daily
Quantity to be supplied	• 1 x 15g tube
	Notes on application: The length of cream equivalent to one
	fingertip unit (the distance from the tip of an adult index finger to
	the first crease) is sufficient to cover an area that is twice that of the
	flat adult hand
Maximum or minimum	Maximum: No longer than 1 week
treatment period	
	2-3 days for insect bites
	5-7 days for conditions such as allergic contact dermatitis
	If the condition worsens or symptoms persist after one
	week seek further advice
Storage	Room temperature
Adverse effects	A detailed list of adverse reactions is available in the SPC, which is
	available from the electronic Medicines Compendium website:
	<u>www.medicines.org.uk</u> and BNF <u>https://bnf.nice.org.uk</u>
Records to be kept	The administration of any medication given under a PGD must be
	recorded within the patient's medical records

Reference number: 93 Valid from: 03/2023 Review date: 09/2025

Version: 2

8. Patient information

Verbal/Written information to be given to patient or carer	 Verbal information must be given to patients and or carers for all medication being administered under a PGD Where medication is being supplied under a PGD, written patient information leaflet must also be supplied A patient information leaflet is available on request Advise to apply sparingly to the affected area
Follow-up advice to be	If symptoms do not improve or worsen or you become unwell, seek
given to patient or carer	medical advice immediately

9. Appendix A

References

- 1. British National Formulary (BNF) available online: https://bnf.nice.org.uk
- 2. Nursing and Midwifery "The code" available online: https://www.nmc.org.uk
- 3. Current Health Care Professions Council standards of practice
- 4. General Pharmaceutical Council standards
- 5. Electronic medicines compendium available online: https://www.medicines.org.uk
- 6. Clinical Knowledge Summaries (2016) Eczema: Atopic http://cks.nice.org.uk/eczema-atopic#!management
- 7. Clinical Knowledge Summaries (2016) Dermatitis: contact http://cks.nice.org.uk/dermatitis-contact#!management
- 8. Clinical Knowledge Summaries (2016) Insect bites and stings http://cks.nice.org.uk/insect-bites-and-stings
- 9. Addison, B, Brown, A, Edwards, R, and G Gray. 2012. Minor illness or Major Disease? 2012

10. Appendix B

Health professionals agreed to practice

- Each registered healthcare professional will hold their own Competency framework which will be signed and agreed by their mentor
- A mentor is defined within the Manx Care policy as any ward/area managers, sisters, senior nurses, GPs, pharmacists or senior paramedics who has completed the PGD training themselves

Reference number: 93 Valid from: 03/2023 Review date: 09/2025

Version: 2